| Literature DB >> 34144684 |
Pruk Chaiyakit1, Surapoj Meknavin2, Natthapong Hongku2, Ittiwat Onklin2.
Abstract
BACKGROUND: Debridement, antibiotics, and implant retention (DAIR) is the recommended treatment for acute hematogenous periprosthetic joint infection (PJI) after total knee arthroplasty (TKA). However, DAIR is associated with a high percentage of unsuccessful outcomes. Since 2007, direct intra-articular antibiotic infusion, which can provide a high concentration of intra-articular antibiotic, has been used in combination with DAIR to improve treatment outcomes among patients in our institution. This study aimed to assess the outcomes of DAIR combined with direct intra-articular antibiotic infusion in patients who presented with acute hematogenous PJI after TKA.Entities:
Keywords: Acute hematogenous; DAIR; Intraarticular antibiotic infusion; Periprosthetic joint infection; Total knee arthroplasty
Mesh:
Substances:
Year: 2021 PMID: 34144684 PMCID: PMC8214261 DOI: 10.1186/s12891-021-04451-x
Source DB: PubMed Journal: BMC Musculoskelet Disord ISSN: 1471-2474 Impact factor: 2.362
Fig. 1Intraarticular double-lumen catheter was placed into left knee joint
Fig. 2This figure illustrates double-lumen catheter which used in our study
Demographic and Clinical data (12 Patients, 15 Knees)
| Age (years) | 65.9 (48–82) |
| Gender | |
| Male | 3 (25%) |
| Female | 9 (75%) |
| BMI (kg./m2) | 27.7 (22.9–42.0) |
| ASA Classification | |
| I | 3 (25%) |
| II | 8 (67%) |
| III | 1 (8%) |
| Comorbidities | |
| Diabetes | 6 (50%) |
| Hypertension | 10 (83%) |
| Chronic renal failure | 1 (8%) |
| Rheumatoid arthritis | 1 (8%) |
| Coronary artery disease | 1 (8%) |
| Duration of symptom (hours) | 107.2 (24–240) |
| Preoperative laboratory data | |
| Serum ESR (mm/hour) | 92.7 (60–155) |
| Serum CRP (mg/L) | 173.4 (14–381) |
| Synovial WBC (Cell/mm3) | 52,736 (3400 - 140,000) |
| Synovial PMN (%) | 96.1 (82–100) |
| Culture | |
| No growth | 10 (66.7%) |
| Group A streptococcus | 2 (13.3%) |
| Group B streptococcus | 1 (6.7%) |
| | 2 (13.3%) |
| Duration of Intraarticular injection (days) | 17.5 (7–24) |
| Time to normal serum CRP (days) | 71.4 (23–312) |
| Length of stay (days) | 36.7 (4–66) |
| Follow up time (months) | 93.3 (56–133) |
ASA American Society of Anaesthesiologists, BMI body mass index, MRSA methicillin-resistant Staphylococcus aureus, CRP C-reactive protein, ESR erythrocyte sedimentation rate, WBC white blood cell, PMN polymorphonuclear neutrophils
Preoperative clinical data in 15 cases
| Age (yrs) | Sex | Site | BMI (kg/m | Comobidity | Preoperative serum CRP (mg/L) | Preoperative serum ESR (mm/h) | Preoperative Synovial WBC / %PMN | |
|---|---|---|---|---|---|---|---|---|
| 72 | Female | Right | 25.8 | CKD DM HT | 82 | 106 | 21,700 / 96 | |
| 82 | Female | Left | 25.6 | DM HT | 14 | 73 | 54,000 / 97 | |
| 70 | Male | Right | 26.1 | HT | 381 | 67 | 27,000 / 98 | |
| 70 | Male | Left | 26.1 | HT | 381 | 67 | 65,700 / 94 | |
| 56 | Male | Right | 31.9 | DM HT DLP | 205 | 67 | 140,000 / 99 | |
| 58 | Female | Left | 42 | HT | 38 | 110 | 3400 / 82 | |
| 59 | Male | Right | 27.8 | HT | 299 | 123 | 40,500 / 97 | |
| 59 | Male | Left | 27.8 | HT | 299 | 123 | 76,000 / 97 | |
| 73 | Female | Left | 26 | DM HT DLP | 251 | 105 | 104,000 / 100 | |
| 71 | Female | Left | 23.8 | DM HT | 113 | 76 | 51,600 / 96 | |
| 48 | Female | Left | 25.6 | HT | 80 | 100 | 70,000 / 98 | |
| 72 | Female | Right | 36.9 | RA | 233 | 63 | 80,000 / 90 | |
| 72 | Female | Left | 22.9 | RA | 134 | 95 | 24,500 / 99 | |
| 69 | Female | Right | 24.2 | DM HT CAD | 56 | 60 | 17,600 / 99 | |
| 58 | Female | Right | 23.1 | AIHA | 35 | 155 | 15,040 / 99 |
BMI body mass index, DM diabetes mellitus, HT hypertension, DLP dyslipidemia, CKD chronic kidney disease, RA rheumatoid arthritis, CAD coronary arterial disease, AIHA autoimmune hemolytic anemia, CRP C-reactive protein, ESR erythrocyte sedimentation rate, WBC white blood cell, PMN polymorphonuclear neutrophils
Details of clinical data in 15 cases
| Duration of intraarticular antibiotics | Culture | Intravenous antibiotics | Intravenous antibiotic duration (Days) | Oral antibiotics | Oral antibiotic duration (Days) | Time to normal serum CRP (Days) | Follow up time (Months) | |
|---|---|---|---|---|---|---|---|---|
| 21 | Negative | Fosfomycin | 30 | Amoxicillin and Clavulanate | 30 | 37 | 99 | |
| 21 | Negative | Fosfomycin | 34 | Ciprofloxacin | 90 | 312 | 125 | |
| 20 | Streptococcus gr. A | Penicillin G and Clindamycin | 45 | Cefdinir | 120 | 111 | 133 | |
| 20 | Streptococcus gr. A | Penicillin G and Clindamycin | 45 | Cefdinir | 120 | 111 | 133 | |
| 13 | Streptococcus gr. B | Fosfomycin | 45 | Amoxicillin and Clavulanate | 90 | 113 | 110 | |
| 20 | Negative | Cefazolin | 5 | Amoxicillin and Clavulanate | 180 | 29 | 70 | |
| 14 | Negative | Cefazolin | 45 | Cephalexin | 30 | 35 | 117 | |
| 15 | Negative | Cefazolin | 45 | Cephalexin | 30 | 35 | 117 | |
| 24 | Negative | Cefazolin | 38 | Amoxicillin and Clavulanate | 90 | 26 | 65 | |
| 7 | Negative | Ciprofloxacin | 24 | Ciprofloxacin | 30 | 35 | 62 | |
| 14 | Negative | Cefazolin | 14 | Amoxicillin and Clavulanate | 60 | 34 | 65 | |
| 12 | MRSA | Vancomycin | 45 | Cephalexin | 60 | 28 | 72 | |
| 19 | MRSA | Vancomycin | 45 | Fucidin | 60 | 107 | 72 | |
| 21 | Negative | Cefazolin | 14 | Amoxicillin and Clavulanate | 60 | 35 | 103 | |
| 21 | Negative | Cefazolin | 14 | Amoxicillin and Clavulanate | 60 | 23 | 56 |
MRSA methicillin-resistant Staphylococcus aureus